Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Applied Therapeutics Inc

Current price
4.15 USD +0.05 USD (+1.22%)
Last closed 4.08 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 466 209 344 USD
Yield for 12 month +219.23 %
21.11.2021 - 28.11.2021

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. Address: 545 Fifth Avenue, New York, NY, United States, 10017

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

11.4 USD

P/E ratio

Dividend Yield

Current Year

+9 993 000 USD

Last Year

+10 660 000 USD

Current Quarter

+190 000 USD

Last Quarter

-667 000 USD

Current Year

+9 640 000 USD

Last Year

-441 000 USD

Current Quarter

+71 000 USD

Last Quarter

-1 014 000 USD

Key Figures APLT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -74 768 496 USD
Operating Margin TTM -11101.58 %
PE Ratio
Return On Assets TTM -51.57 %
PEG Ratio
Return On Equity TTM -612.33 %
Wall Street Target Price 11.4 USD
Revenue TTM -477 000 USD
Book Value 0.59 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -98.2 %
Dividend Yield
Gross Profit TTM
Earnings per share -1.91 USD
Diluted Eps TTM -1.91 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics APLT

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History APLT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation APLT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 49.7603
Price Sales TTM 54.676
Enterprise Value EBITDA -7.7477
Price Book MRQ 4.8902

Financials APLT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators APLT

For 52 weeks

1.18 USD 9.39 USD
50 Day MA 5.16 USD
Shares Short Prior Month 4 473 645
200 Day MA 3.43 USD
Short Ratio 6.13
Shares Short 4 570 858
Short Percent 4.47 %

Dynamics of changes in the value of assets




430.16 USD Microsoft Corporation +3.16 (+0.74%)
Detailed analytics

ETF funds



14.70 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.1 (+0.64%)
Detailed analytics



2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics